Skip to content
Bliss GVS Pharma logo

Bliss GVS Pharma

BLISSGVS NSE
₹619.55 −11.75 (−1.86%)
P/E
48.18
View as Markdown
MCP
Close 4 Nov 2026 ₹619.55 +467.57 +308% 1Y
Start ₹151.98

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
16.90%
Debt to Equity
0.02
EPS (TTM)
₹12.86
Book Value
₹121.29
Market Cap
—
P/E (TTM)
48.18
P/B
5.11
ROE
11.80%
Dividend Yield
0.24%
EBITDA
₹238 Cr
52W High
₹739.90
52W Low
₹118.00
Day Range
₹601.00 – ₹637.00
Volume
1,84,275

Peer Comparison

Healthcare › Pharmaceuticals

Bliss GVS Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Bliss GVS Pharma (this company)
₹619.5548.18₹6,695 Cr5.110.24%11.80%16.90%₹1,005 Cr₹142 Cr
Median 8 companies₹1,587.7043.50₹1,25,337 Cr4.940.44%16.25%17.35%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

surveillance:ASM4pledge:96%

Category scores

Quality
48
Average
Returns, margins, earnings quality 22% weight
Valuation
51
Average
Cheap vs sector & own history 24% weight
Growth
61
Good
Sales & profit trajectory 9% weight
Financial Health
83
Strong
Solvency, leverage, coverage 9% weight
Momentum
95
Strong
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM4 ≤ 40, pledge>75% ≤ 40).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Stock is trading at 5.90 times its book value
  • The company has delivered a poor sales growth of 9.94% over past five years.
  • Company has a low return on equity of 10.2% over last 3 years.
  • Company has high debtors of 204 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish874
OscillatorsBearish270
Moving AveragesStrong Bearish604

Key readings

RSI (14)
44.06
Neutral
MACD (12,26,9)
−7.44
Bearish
SMA (50)
657.09
Bearish
SMA (200)
413.48
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+5.42%
5Y+9.95%
3Y+7.22%
1Y+14.44%
TTM+20.65%

Net profit

Net profit growth by window
10Y+3.05%
5Y+12.78%
3Y+20.58%
1Y+50.00%
TTM+25.66%

Operating cash flow

Operating cash flow growth by window
10Y+2.09%
5Y+16.78%
3Y+59.90%
1Y+31.13%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−10.40 pp
5Y−0.42 pp
3Y+2.56 pp
1Y+2.44 pp
TTM+3.73 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹798 Cr
Mar 2018₹815 Cr
Mar 2019₹899 Cr
Mar 2020₹689 Cr
Mar 2021₹577 Cr
Mar 2022₹747 Cr
Mar 2023₹752 Cr
Mar 2024₹770 Cr
Mar 2025₹810 Cr
Mar 2026₹927 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹113 Cr
Mar 2018₹89.00 Cr
Mar 2019₹127 Cr
Mar 2020₹95.00 Cr
Mar 2021₹74.00 Cr
Mar 2022₹23.00 Cr
Mar 2023₹77.00 Cr
Mar 2024₹82.00 Cr
Mar 2025₹90.00 Cr
Mar 2026₹135 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Bliss GVS Pharma Ltd is a near debt-free pharmaceutical company with a market cap of Rs.5,385 Cr trading at a PE of 39.8x. The stock has delivered a 224% return over the past year driven by a 56% TTM profit growth, though underlying sales growth remains modest at 15% TTM and 5-year CAGR of 10%.

Bull Case 7
  • Company is almost debt-free, having actively reduced its debt, which strengthens the balance sheet and lowers financial risk
  • TTM profit growth of 56% indicates a sharp acceleration in earnings relative to the 5-year profit CAGR of 14%
  • Stock has delivered a 1-year return of 224%, reflecting strong market re-rating and momentum
  • 3-year compounded profit growth of 23% outpaces 3-year sales growth of 7%, suggesting improving operating leverage and margins
  • ROE has improved to 12% in the last year from a 3-year average of 10% and 5-year average of 9%, indicating an upward trajectory in capital efficiency
  • TTM sales growth of 15% marks an acceleration from the 10-year compounded sales CAGR of just 5%
  • 5-year stock CAGR of 35% and 10-year CAGR of 17% demonstrate sustained long-term wealth creation
Bear Case 7
  • PE ratio of 39.8x is elevated for a company with 5-year sales CAGR of only 10%, suggesting the stock may be pricing in optimistic growth assumptions
  • Debtor days stand at 204 days, indicating significant working capital locked in receivables and potential collection risk
  • Other income of Rs.67.5 Cr forms a material portion of earnings, meaning core operating profit may be lower than headline numbers suggest
  • Price-to-book ratio of 4.49x is high relative to the 3-year ROE of only 10.2%, implying the market is paying a premium not fully justified by returns on equity
  • 5-year compounded sales growth of approximately 10% and past 5-year reported sales growth of 9.94% remain below peer benchmarks in the pharma sector
  • 3-year ROE of 10% is below the 15%+ threshold typically expected of quality compounders in healthcare
  • Dividend yield of only 0.3% offers negligible income support to investors at current valuations

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Bliss GVS Pharma is executing well with 18% revenue growth and nearly 50% profit growth in FY26, signaling strong operational leverage. The Anupam Rasayan open offer at ₹299 per share provides a near-term floor and validates strategic value. Leadership transition to a new CEO introduces some execution uncertainty but no visible negatives. The trend is improving, with earnings momentum and potential strategic synergies from the acquisition likely to drive further interest.

Positives 2
  • Strong FY26 revenue and profit Jun 23

    Consolidated revenue rose 18.26% YoY to ₹1,00,064.26 Lakh in FY26, with net profit surging 49.27% to ₹13,472.77 Lakh. Final dividend of ₹1.00 per share recommended.

  • Anupam Rasayan open offer at ₹299 Jun 9

    Anupam Rasayan announced an open offer to acquire up to 26.00% of Bliss GVS at ₹299.00 per share (₹829.03 crore), following a share purchase agreement for 43.30% stake.

Neutral 2
  • New CEO appointed from July 15 Jul 3

    Rahul Adakmol appointed CEO effective July 15, 2026, and Santosh Parab as Additional Director. Narsimha Kamath stepped down as CEO.

  • 41st AGM set for July 15 Jun 19

    Bliss GVS Pharma announced its 41st AGM on July 15, 2026, via video conferencing with ₹1.00 per share final dividend on the agenda.

Quarterly Results

₹ Cr
BLISSGVS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
160
212
201
198
184
218
210
198
207
244
218
257
286
313
Expenses
135
158
157
170
149
176
181
177
166
201
183
213
209
233
Operating Profit
24
54
44
28
34
41
30
21
41
43
35
44
76
81
OPM %
15%
26%
22%
14%
19%
19%
14%
11%
20%
18%
16%
17%
27%
26%
Other Income
5
13
5
−24
4
5
15
12
35
8
16
11
10
8
Interest
1
1
2
2
2
4
1
2
5
3
1
2
1
3
Depreciation
6
6
7
7
7
7
8
8
8
8
8
9
10
10
PBT
22
59
40
−4
30
36
36
23
63
41
41
45
75
75
Tax %
34%
27%
27%
24%
26%
28%
29%
29%
30%
30%
39%
18%
32%
29%
Net Profit
14
43
29
−5
22
26
26
17
44
29
25
37
51
53
EPS (₹)
1.41
4.05
2.64
−0.87
1.97
2.31
2.26
1.47
4.08
2.58
2.2
3.36
4.72
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
BLISSGVS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
407
547
798
815
899
689
577
747
752
770
810
927
1,005
Expenses
304
391
596
618
739
566
471
629
634
620
683
760
806
Operating Profit
103
156
203
197
160
123
107
118
117
151
127
168
199
OPM %
25%
29%
25%
24%
18%
18%
18%
16%
16%
20%
16%
18%
20%
Other Income
20
24
12
−8
35
26
20
−42
18
0
36
67
45
Interest
16
19
20
23
4
8
6
5
10
7
8
12
7
Depreciation
11
13
20
21
9
13
17
17
19
26
29
33
35
PBT
96
148
175
145
182
129
104
54
106
117
126
190
202
Tax %
36%
32%
36%
39%
30%
26%
29%
57%
28%
30%
28%
29%
—
Net Profit
61
100
113
89
127
95
74
23
77
82
90
135
142
EPS (₹)
5.81
8
7.95
5.7
11.99
9.43
6.64
1.45
6.8
7.21
8
12.21
12.86
Div. Payout %
12%
6%
8%
18%
8%
5%
8%
34%
7%
7%
6%
4%
—

Balance Sheet

₹ Cr
BLISSGVS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10
10
10
10
10
10
10
10
10
10
11
11
Reserves
327
402
476
526
636
725
798
808
873
957
1,040
1,182
Borrowings
160
132
225
118
102
126
122
109
102
100
88
22
Other Liabilities
166
218
311
206
157
168
147
181
171
145
163
278
Total Liabilities
662
762
1,023
860
905
1,030
1,077
1,109
1,157
1,212
1,301
1,492
Fixed Assets
234
225
305
143
146
242
234
281
379
370
406
459
CWIP
0
9
4
0
47
0
2
22
3
8
21
6
Investments
0
0
0
0
0
0
0
2
8
4
4
5
Other Assets
428
527
714
717
712
788
840
803
768
830
871
1,022
Total Assets
662
762
1,023
860
905
1,030
1,077
1,109
1,157
1,212
1,301
1,492

Cash Flow

₹ Cr
BLISSGVS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
38
113
289
18
40
47
64
135
34
103
106
139
Investing
−29
−50
−249
48
−79
−40
−45
−103
−6
−83
−75
−38
Financing
−42
−40
−10
−76
17
−6
−21
−24
−25
−21
−30
−89
Net Cash Flow
−34
23
30
−10
−22
0
−2
9
3
−1
0
11
Free Cash Flow
5
101
186
−7
2
−12
55
63
−59
75
33
84
CFO/OP
45
101
160
29
−8
69
87
143
67
91
112
108

Ratios

BLISSGVS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
222
201
116
134
187
290
293
192
187
192
198
204
Inventory Days
69
55
50
55
46
64
110
116
94
113
111
129
Days Payable
165
153
100
55
47
75
82
86
79
58
63
89
Cash Conversion Cycle
126
102
67
134
186
279
321
221
202
247
246
244
Working Capital Days
105
84
−10
135
154
232
264
179
192
207
198
214
ROCE %
23%
31%
29%
27%
26%
18%
12%
14%
12%
14%
12%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bliss GVS Pharma insights

70 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 50.07%
  • Public 22.97%
  • Others 12.31%
  • DIIs 9.62%
  • FIIs 5.03%

95.77% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY20 concall · Aug 2019
    PPT
  • Concall · May 2019
    PPT
  • Concall · Feb 2019
    PPT
  • Concall · Nov 2018
    PPT
  • Q1 FY19 concall · Aug 2018
    PPT

Frequently Asked Questions about Bliss GVS Pharma

What does Bliss GVS Pharma Ltd do?
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
Where is Bliss GVS Pharma Ltd (BLISSGVS) listed?
Bliss GVS Pharma Ltd trades as BLISSGVS on the NSE and under code 506197 on the BSE.
Which sector does Bliss GVS Pharma Ltd belong to?
Bliss GVS Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd trades at a PE ratio of 48.18 as of 4 Nov 2026, on earnings per share of ₹12.86, against a book value of ₹121.29 per share.
What is the 52-week high and low of Bliss GVS Pharma Ltd?
Over the last 52 weeks Bliss GVS Pharma Ltd has traded between ₹118 and ₹739.9 as of 4 Nov 2026.
Does Bliss GVS Pharma Ltd pay dividends?
Bliss GVS Pharma Ltd has a dividend yield of 0.24%.
What is the Return on Equity (ROE) of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd reported a return on equity of 11.80%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Website blissgvs.com
CEO Dr. Vibha Gagan Sharma
Employees 966
Listed 30 Jul 2010
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BLISSGVS.md for Bliss GVS Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month